Why This Marijuana Stock Crashed 18.5% in August
Arizona's attorney general is suing Insys Therapeutics (NASDAQ: INSY) over its marketing of the fentanyl opioid spray, Subsys, and that news caused the company's shares to tumble 18.5% in August, according to S&P Global Market Intelligence.
Insys Therapeutics has launched its marijuana drug Syndros. However, uncertainty over demand for it and ongoing concerns regarding the marketing of Subsys remain major headwinds.
IMAGE SOURCE: INSYS THERAPEUTICS.
Source: Fool.com
INSYS Therapeutics Inc Stock
€0.042
5.000%